Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Panteleimon Charitos"'
Autor:
Pascal Urwyler, Marina Leimbacher, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi, Michael Osthoff
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundConestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation.MethodsWe conducted a randomized, open-label, multi-national clinical trial in which hospitalized adults at risk for progression to severe COVID-19 were
Externí odkaz:
https://doaj.org/article/13e39c08209c4b4b9e955d59ae6dbb21
Autor:
Flavio Bruni, Panteleimon Charitos, Maurin Lampart, Stephan Moser, Martin Siegemund, Roland Bingisser, Stefan Osswald, Stefano Bassetti, Raphael Twerenbold, Marten Trendelenburg, Katharina M. Rentsch, Michael Osthoff
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThromboinflammation may influence disease outcome in COVID-19. We aimed to evaluate complement and endothelial cell activation in patients with confirmed COVID-19 compared to controls with clinically suspected but excluded SARS-CoV-2 infect
Externí odkaz:
https://doaj.org/article/83b094027c554dbbae667da96e16fbad
Autor:
Panteleimon Charitos, Ingmar A. F. M. Heijnen, Adrian Egli, Stefano Bassetti, Marten Trendelenburg, Michael Osthoff
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
AimsAlthough the exact factors promoting disease progression in COVID-19 are not fully elucidated, unregulated activation of the complement system (CS) seems to play a crucial role in the pathogenesis of acute lung injury (ALI) induced by SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/1cdfa175ee6b44ce863c0bacb6533711
Autor:
Pascal Urwyler, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi, Michael Osthoff
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study objective is to investigate
Externí odkaz:
https://doaj.org/article/94b47821094d40348464c6a01a92f215
Autor:
Pascal Urwyler, Stephan Moser, Panteleimon Charitos, Ingmar A. F. M. Heijnen, Melanie Rudin, Gregor Sommer, Bruno M. Giannetti, Stefano Bassetti, Parham Sendi, Marten Trendelenburg, Michael Osthoff
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (co
Externí odkaz:
https://doaj.org/article/73299d9df6f94090a0e9e649115d6273
Autor:
Lars C. Huber, Michael Osthoff, Melina Stüssi-Helbling, Reto Thoma, Stephan Moser, Marcelo R. Bacci, Werner C. Albrich, Pascal Urwyler, Johannes Sumer, Adrián Camacho-Ortiz, Panteleimon Charitos, Ingmar Heijnen, Parham Sendi, Marten Trendelenburg
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Urwyler, Pascal; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2021). Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 22(1), p. 1. BioMed Central 10.1186/s13063-020-04976-x
Trials
Urwyler, Pascal; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2021). Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 22(1), p. 1. BioMed Central 10.1186/s13063-020-04976-x
Trials
Objectives Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study objective is to investigate the effi
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.